Literature DB >> 6764604

The abnormally aged brain. Its blood flow and oxidative metabolism. A review - part II.

S Hoyer.   

Abstract

The most common brain disease in middle and old age is dementia. Primary dementias comprise degenerative (dementia of Alzheimer type, DAT) and cerebrovascular (dementia of vascular type, DVT) types. These dementia types differ in morphological, clinical, and pathobiochemical terms. In DAT, large amounts of neuritic plaques and neurofibrillary tangles or paired helical filaments, are present throughout the whole brain cortex, but particularly numerous in temporal areas. Here and in hippocampus, the presynaptic cholinergic system seems to be predominantly affected. In DVT, multiple small infarcts are scattered over brain cortex and white matter obviously due to disturbances in cerebral microcirculation. Dementia is closely related to disturbances in brain blood flow and oxidative metabolism. In the beginning of DAT, cerebral blood flow and CMR-oxygen are found to be in normal ranges, but CMR-glucose is reduced. In DVT, cerebral blood flow and CMR-oxygen are also within the normal range, but CMR-glucose is found to be abnormally increased. When dementia symptoms are well developed in DAT, the same relationship between circulation and metabolism are found. Well-developed DVT symptoms seem to be associated with changes in blood flow and metabolism similar to variations after ischemic/anoxic lesions. In the beginning of both dementia types, a close correlation exists between cerebral blood flow and CMR-oxygen, but there is a dissociation from CMR-glucose. In the further course of both dementia types, cerebral blood flow and metabolism run into a final common path of a low functional level. No distinction between the dementia types is possible. In general, severity of dementia symptoms are correlated to the deviation of cerebral blood flow and metabolism from normal. There is much evidence that dementia, i.e. abnormal cerebral aging is different from normal cerebral aging. Dementia is not a form of accelerated cerebral aging.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6764604     DOI: 10.1016/0167-4943(82)90021-8

Source DB:  PubMed          Journal:  Arch Gerontol Geriatr        ISSN: 0167-4943            Impact factor:   3.250


  8 in total

1.  Glucose metabolism as the site of the primary abnormality in early-onset dementia of Alzheimer type?

Authors:  S Hoyer; K Oesterreich; O Wagner
Journal:  J Neurol       Date:  1988-01       Impact factor: 4.849

Review 2.  The debate continues - What is the role of MCU and mitochondrial calcium uptake in the heart?

Authors:  Joanne F Garbincius; Timothy S Luongo; John W Elrod
Journal:  J Mol Cell Cardiol       Date:  2020-04-27       Impact factor: 5.000

Review 3.  Brain metabolism in health, aging, and neurodegeneration.

Authors:  Simonetta Camandola; Mark P Mattson
Journal:  EMBO J       Date:  2017-04-24       Impact factor: 11.598

Review 4.  Quintessential risk factors: their role in promoting cognitive dysfunction and Alzheimer's disease.

Authors:  Mak Adam Daulatzai
Journal:  Neurochem Res       Date:  2012-08-12       Impact factor: 3.996

5.  Cognitive performance and age-related changes in the hippocampal proteome.

Authors:  W M Freeman; H D VanGuilder; C Bennett; W E Sonntag
Journal:  Neuroscience       Date:  2008-12-14       Impact factor: 3.590

Review 6.  Brain Metabolic Alterations in Alzheimer's Disease.

Authors:  Carlos G Ardanaz; María J Ramírez; Maite Solas
Journal:  Int J Mol Sci       Date:  2022-03-29       Impact factor: 5.923

7.  Cerebral blood flow in Alzheimer's disease.

Authors:  Alex E Roher; Josef P Debbins; Michael Malek-Ahmadi; Kewei Chen; James G Pipe; Sharmeen Maze; Christine Belden; Chera L Maarouf; Pradeep Thiyyagura; Hua Mo; Jesse M Hunter; Tyler A Kokjohn; Douglas G Walker; Jane C Kruchowsky; Marek Belohlavek; Marwan N Sabbagh; Thomas G Beach
Journal:  Vasc Health Risk Manag       Date:  2012-10-23

Review 8.  The Erythrocytic Hypothesis of Brain Energy Crisis in Sporadic Alzheimer Disease: Possible Consequences and Supporting Evidence.

Authors:  Elena Kosenko; Lyudmila Tikhonova; Gubidat Alilova; Amparo Urios; Carmina Montoliu
Journal:  J Clin Med       Date:  2020-01-12       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.